<SEC-DOCUMENT>0000950170-25-105011.txt : 20250807
<SEC-HEADER>0000950170-25-105011.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807160842
ACCESSION NUMBER:		0000950170-25-105011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Trevi Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001563880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450834299
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38886
		FILM NUMBER:		251194011

	BUSINESS ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		16TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-304-2499

	MAIL ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		16TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>trvi-20250807.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-07T15:12:24.6579+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:trvi="http://www.trevitherapeutics.com/20250807" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_21415a5a-25b6-4d36-9d50-b206b674eff4" name="dei:EntityCentralIndexKey" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec">0001563880</ix:nonNumeric><ix:nonNumeric id="F_2ea59ac0-636a-4812-b0df-17535db4755f" name="dei:AmendmentFlag" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="trvi-20250807.xsd"/></ix:references><ix:resources><xbrli:context id="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563880</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03521852-24fe-46e3-bcbe-cdf12f69357c" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c2313ba-5615-4b4a-85e3-236861df663f" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 7, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f4dc316-20ad-4497-b361-2aaab7e98c93" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:38.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6b1bb072-f980-4ea3-bc80-9eb312dc37ce" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ef7bcaf7-2de3-4f1f-9bbd-383dd445b9a5" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-38886</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3b7dc38e-0dd1-4be2-b801-2f7b37fe551c" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45-0834299</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Incorporation)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:22%;box-sizing:content-box;"/>
     <td style="width:39%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;"><ix:nonNumeric id="F_796ba6fd-2d20-4e5f-9e88-142aa4bc4a25" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">195 Church Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;"><ix:nonNumeric id="F_6f1819c5-3257-4b08-b3c1-5bef25aacce9" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> Floor</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_41eb83df-054e-4858-8281-4dcfb396f00c" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New Haven</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_e8d598c4-40a3-4969-9167-a96dbabb0d31" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Connecticut</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2df65019-8178-4577-9816-191e5919ed77" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">06510</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f848fa40-ab7e-4d99-92bc-5d93974706f4" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(203)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14886cf6-b687-42c4-8452-2aa095f0c058" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">304-2499</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_04376e39-9e3f-4469-a380-63af9c40dcbe" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8a0eb1e7-3bdc-42fa-9005-b45955f5c179" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e918ce6d-143f-4d96-bfdc-bbf10cdc2d14" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d393c0d1-6612-4899-9a71-e5a6520f02a1" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:39%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_945c08d7-8079-4baf-94cb-993d3f58f9cb" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f95a8cfa-fc79-4b4a-a81e-b1c0c36931b6" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRVI</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_01a52a36-19dc-4f5c-b373-d348c6124db9" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_094b2159-402a-49c0-869e-b575a2e40ab9" contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information provided under Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8.362%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:90.578%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="trvi-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press release issued by the Company on August 7, 2025</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    </tr>
    <tr style="height:5.05pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	The exhibit shall be deemed to be furnished, and not filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44.969%;box-sizing:content-box;"/>
     <td style="width:9.962%;box-sizing:content-box;"/>
     <td style="width:4.001%;box-sizing:content-box;"/>
     <td style="width:41.068%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TREVI THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 7, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lisa Delfini</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Lisa Delfini</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Financial Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.69in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>trvi-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img251553556_0.jpg" alt="img251553556_0.jpg" style="width:216px;height:129px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">      </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Closed $115 million underwritten offering with expected cash runway into 2029</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Management to host a conference call and webcast today at 4:30 p.m. ET&#x202f;&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">New Haven, Conn., August 7, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x2013; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#153; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended June 30, 2025, and provided business updates.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#34;The recently received full data set from our CORAL trial for chronic cough in patients with IPF bolsters the statistically-significant topline results presented in June. This data marks a major milestone for Trevi as it shows consistency and clinically meaningful benefit for these patients,&#x201d; said Jennifer Good, President and CEO of Trevi Therapeutics. &#x201c;Chronic cough is a debilitating and underserved condition for patients with IPF, and these results, along with the positive RCC data from our RIVER trial announced earlier this year, reinforce our belief in Haduvio&#x2019;s potential to transform care of chronic cough and the lives of these patients. We expect our current cash and investments to provide us with cash runway into 2029, giving us the financial strength to advance Haduvio through late-stage development and several key clinical milestones, as well as enabling pre-commercial planning activities.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Second Quarter 2025 Financial Results and Recent Business Highlights&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Positive topline results</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> from the Phase 2b CORAL trial evaluating Haduvio for the treatment of chronic cough in patients with IPF (N=165) were announced in June 2025. Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups. The 108 mg BID, 54 mg BID, and 27 mg BID dose groups achieved statistically-significant reductions from Baseline of 60.2% (p&lt;0.0001), 53.4% (p&lt;0.0001), and 47.9% (p&lt;0.01), respectively, compared to a placebo reduction from Baseline of 16.9%.1 The Company plans to request an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2025 to align on the Phase 3 program. The Company is preparing to initiate the Phase 3 program in the first half of 2026.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#0e101a;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#0e101a;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Additional analyses from the Phase 2b CORAL trial showed positive results with Haduvio on the Leicester Cough Questionnaire (LCQ) Total Score for the 108 mg BID and 54 mg BID dose groups, increasing the LCQ score by 3.4 points (p=0.01) and 3.7 points (p=0.01), respectively. A 1.3-point increase from Baseline is considered clinically meaningful. The LCQ is considered an important measure of quality of life for patients suffering from chronic cough.</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#0e101a;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#0e101a;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Completed a </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$115 million underwritten offering</font></font><font style="color:#0e101a;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> in June 2025, enabling continued advancement of Haduvio&#x2019;s clinical programs. The Company e</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">nded the second quarter of 2025 with $203.9 million in cash, cash equivalents and marketable securities, with expected cash runway into 2029.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Second Quarter 2025 Financial Highlights&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development (R&amp;D) expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> R&amp;D expenses for the second quarter of 2025 decreased to $9.4 million from $10.0 million in the same period in 2024, primarily due to decreased clinical development expenses for the Company's Phase 2a RIVER trial, Human Abuse Potential (HAP) study, and Phase 2b CORAL trial, all of which were actively enrolling patients in the prior year period.  These decreases were partially offset by increased costs for the Company's recently initiated Phase 1 drug-drug interaction study, and personnel and related expenses.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative (G&amp;A) expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> G&amp;A expenses for the second quarter of 2025 increased to $4.3 million from $3.3 million in the same period in 2024, primarily due to an increase in professional fees, and personnel and related expenses.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Income, net: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other Income, net for the second quarter of 2025 increased to $1.4 million from $0.9 million in the same period in 2024, primarily due to an increase in interest income from higher invested cash equivalent and marketable securities balances.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For the second quarter of 2025, the Company reported a net loss of $12.3 million compared to the net loss of $12.4 million in the same period in 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call/Webcast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">live audio webcast</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> will be accessible from the 'Investors &amp; News' section on the Company's website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.TreviTherapeutics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Upcoming Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company plans to participate in the following events:&#x202f;&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">August 11-13: Stifel&#x2019;s 2025 Biotech Summer Summit </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 3-5: Wells Fargo 2025 Healthcare Conference </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 3-5: Cantor Global Healthcare Conference 2025 </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 8-10: H.C. Wainwright &amp; Co. 27th Annual Global Investment Conference</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 8-10: Morgan Stanley 23rd Annual Global Healthcare Conference</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 17-19: 2025 Leerink Partners Biopharma Summit </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">September 27-October 1: European Respiratory Society (ERS) Congress </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Trevi Therapeutics, Inc.&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> &#x202f;<br>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">therapy Haduvio&#153; (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in chronic cough patients with IPF and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting &gt;8&#x2005;weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For more information, visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.TreviTherapeutics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> and follow Trevi on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (formerly Twitter) and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x202f;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements &#x202f; <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Statements contained in this press release regarding matters that are not historical facts are &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data, expectations regarding Trevi&#x2019;s uses and sufficiency of capital, and other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi&#x2019;s product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Balance Sheet Data</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(amounts in thousands)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.633%;box-sizing:content-box;"></td>
     <td style="width:1.52%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.163%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.52%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:13.163%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">June 30,<br>2025</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,<br>2024</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">117,058</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">34,097</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Marketable securities</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">86,827</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">73,525</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Working capital</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">197,987</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">98,919</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">208,339</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">110,900</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Stockholders' equity</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">198,493</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">99,644</font></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Statement of Operations Data</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(amounts in thousands, except per share amounts)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.77%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.14%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.198%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Three Months Ended<br>June 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Six Months Ended<br>June 30,</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9,389</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10,021</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">17,200</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">18,825</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4,333</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3,268</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,992</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">6,370</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">13,722</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">13,289</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,192</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,195</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(13,722</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(13,289</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(25,192</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(25,195</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other income, net</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,400</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">929</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2,519</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,925</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss before income taxes</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,322</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,360</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(22,673</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(23,270</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Income tax benefit</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">21</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">32</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">16</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,301</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,352</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(22,641</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(23,254</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share outstanding</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.09</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.12</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.18</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.23</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">130,350,391</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">101,041,573</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">124,015,763</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">100,279,393</font></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Jonathan Carlson</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Trevi Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(203) 654 3286</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">carlsonj@trevitherapeutics.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Rosalia Scampoli</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">914-815-1465</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">rscampoli@marketcompr.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat (mITT) population. Inclusion of the patient in the placebo group would have resulted in an increased cough frequency from Baseline in the placebo group and much greater placebo-adjusted differences.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img251553556_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img251553556_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $H >\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHIXQ+!(KJW*LIR#2'<=11D=<T9% !1110 4444 %%%% !1110 4444 %%%%
M!2%EZ9I:_/\ _P"#C3X]?&K]G;]B3P_XW^!'Q4U[PCK$_P 1+.TFU+P_J4EK
M,\#6EXS1ED()4LBDCIE1Z5TX/#2QF*A0B[.3M<Y,?C(8#!SQ$U=15[(_0#</
M6C</6OY3Q_P5/_X*1X_Y/C^)_P#X6%U_\71_P]/_ ."D?_1\?Q/_ /"PNO\
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M_CE>E_L=?\'%_P"T-^TI^U+X#^ GB/X >#=-L?%WB:VTRZOK&ZNVF@CD;!9
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MVT^3/SCCS.N)\BSSDP^(DJ51*459:=&M5T:OZ-'Z6I_P<R?M*-_S;CX']O\
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M_9_\&_\ @9=__%U(G_!P_P#M"2?\T!\&C_M[N_\ XNOSUA@)Y?\ _55B./\
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M>WEZ,HY609^ZPZ$?Y&*]*IA8WYJ;Y7^!Y='%RY>2JN:/X_U_5S2\<_"?Q/X
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MHE+]#!2/(VJ*L11A12H@4<5/# 2>17VQ^?V[!% 7.:_:S_@GJ,?L7?#P#_H
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MY<._E8_[L2^D4:XSC!<\G!;CYUGN/$/CCQ(+B]N);[4=1N%4-(<L[L< >PZ
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M&LD+AD8!E93D,#T(]17RW^U-H%SI/Q?NK^0?N]2M8;B-OH@C(_./]17G9?\
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M (*'W7Q.\"^&_A/^T%K&WQ)+IMO'I6OW4G_(4.P ),QZ3GLQ_P!83@_/]_\
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MKYTU/2QI>L7>E_\ /M=21?\ ?+$?TKZ41 !TKY_\7A)?&.K2QCY?[2GQCO\
MO#7TV!;YI(^1S**Y8F7#!CFOV0_8(&/V// (Q_S E_\ 0VK\>8H=W.*_8C]@
MWC]D'P$,?\P-?_0VKQ>+G_L5/_%^C/H."(VQ]1_W?U1ZY1117Y^?I@4444 %
M%%% !1110 4444 %%%% !1110 4$9&*** /@G_@M#_P2*M?V[O"L?QI^"L%O
M9_%+P]8^3#'(RQQ>(+1<L+61S@)*I)\J0G'S%&PI#)^!/C/P1XQ^&_BN_P#
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M6WU31?!^FV&HVZR*XCGAM8XY%#*2&PRD9!(/:O ?^"SG[+7QH_;!_8U;X/?
M;PU#JVO'Q587WV6?4(K9?)B$N]M\K*O&X<9R:_)\OJ48YW3G-KEY[MO:U^Y^
M_9Q1Q,N%ZM.E%N?L[)):WMLEW/Q6L?B=\(?V@/#_ /PB?C+&F7C-NCCN9@NR
M3'WH9<;2>V#@GI@BO,OB7\ /&?PZ=[Z"W;4M+'*WULG*+_TT3DK]>5]^U?2
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MO_(^?8H<#(K]@/V$@5_9$\!@_P#0#7_T-J^!X_\ @F)^V*OS'X<VG_@\M?\
MXY7Z(_LJ>!/$WPR_9Y\*^ ?&5BMMJFEZ8(;R!95D"/N8XW*2#U[&O%XFQF%Q
M&$A&E-2?-T:?1GT/"6!QF%QDY5J<HIQZIKJNYZ#1117Q)]\%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117-_$'XP_"SX4?9?\
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M8M-?>M :<=&%%%%;""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"W2/]E7QQ;I]V/PW,%_!:\K_ ."3:@?LZ:HV?^9NN!_Y+VU>K?MC@M^RWXZ
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M97*R>Y4&OU-C<.@=6R#SD=Z^6/VX/V:-*L?V+M+T7PQ:JTWP\AMYH9%CR\L
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MF6*R^A.A@*G)[.,TXIS4??E"+U47]ST72RBO+W8J3NS\\?\ @GG^S/\ "O\
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M[7"A/V7O'2C^'PO=?^BS7:>#MO\ PB.EE!\O]FP8S_US%<7^UT,_LP^.^/\
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MW?L6****^\, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>trvi-20250807.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-07T15:12:24.6821+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.trevitherapeutics.com/20250807" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:trvi="http://www.trevitherapeutics.com/20250807" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation" id="DisclosureDocumentAndEntityInformation">
        <link:definition>75000 - Disclosure - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation" xlink:href="trvi-20250807.xsd#DisclosureDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001563880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Trevi Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0834299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">195 Church Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">16th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-2499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRVI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="trvi-20250807.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Disclosure - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="trvi-20250807.htm">trvi-20250807.htm</File>
    <File>trvi-20250807.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "trvi-20250807.htm": {
   "nsprefix": "trvi",
   "nsuri": "http://www.trevitherapeutics.com/20250807",
   "dts": {
    "inline": {
     "local": [
      "trvi-20250807.htm"
     ]
    },
    "schema": {
     "local": [
      "trvi-20250807.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation",
     "longName": "75000 - Disclosure - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a6af76a8-b5f6-42cc-bfe9-771c554351ec",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trvi-20250807.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a6af76a8-b5f6-42cc-bfe9-771c554351ec",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "trvi-20250807.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.trevitherapeutics.com/20250807/taxonomy/role/DisclosureDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-25-105011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-105011-xbrl.zip
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MN0,%%#*Q#991_@A0D_:A L,56#]P@XPX3D-%C2T76IU1DF#A_( - HU-CR=
M\I9G$Y0X@&8 60+Z!N,D$3[\AKZV>HGV6L@;*2>(\M6*-/=*$RU/6KR39.4"
M>SK+NW?G?LT2R!Z&%X 2T;1T!>$":(J7Q.\'H> %Z4O*!D,05(>0 G)J"-J/
M] +L(W'"<DQRQ"R/S1:>,AKT%J/+XQ8L59*.W#^@NYR:!0D#)K/"@AR2K,_
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MP&'3C?GD_7>'S7XV"-__%U!+ P04    "  3@0=;Y6K[DW )  !R;P  $0
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M9SD1FOTBKMB9FO"XO'&@LDQ-X%[30Q[)4=R+Q+!J"#_#U>);:HE% K#MDH9
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MP3SX*5)EP(%LK\)WP!/+P6I$S][_Z]U9,:(SA!$\C:1 1@!]4_CF0=LR!@+
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ML8,0+"\NECID $L'1W[SD+7\#FMTN@UV8"QT7&RXL;-T7%\@SORABE<OJ:6
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MH&_&SDA.9&:J6WCS]\X&P5C?5WIVQJ'=V6:FDDQ_\; QKVC<!+1YAJ6=[6U
MLJU.RHN30>"'RD?'<+MJ+).3ZJB-HBXU<K(J@6?JT>F%,^?,Z6O>X@MN$#[;
M4F3"81,SY^CB2S-=A6$Y3_! 89O*4*::C[XEK.4R#EPBIJO#Y\RY;=C[ZDR[
M\@J$V\6>OR4739]O_VR[,7?!$ M<B7A:"@%VL<[.C'39,!_H2R4,J"CKDU0"
M!X%.5M38MIL.[Y*44C!Z-X1UQDI3UB0W>^(]4Y5O?L3*$_KF#JU+%4X1 FOC
M4.*!F(N'NU5GL2T.IAW@OGF9R9C;^;>RW/KLI#U^XQFC0BC+924$+(HTP"J$
M(I1&/DL>E#J'*6_4M5O2-5_"!9-IA68*4Q$]+)(W_3OY5.H*-QDB,YTJK@%3
M@ ,X78J1)E:2$Z/IS39NBOV2\!)N>P5QA;C2)KJUHSWC2OGN90H3@XV#5XND
MZN'\@. $]8)BEFFUV""#@6Y=..2IP+-M I6CV E]LQLR'I?<8CC!/+%9LHJV
M67UBK\2)JDK=3/]N'<DZ#R]+>#S$'%71G$I$6J38G#."M,9J-Q?BT!JKG1U:
M6F/U&%[.T/J&-5HXM=6"_5VNLK:E%+-Q:8Z*4FY16;<-3>J/Z)C[C=IO=QS:
M_='4HV[Y]M1N,"RX_*8ZS6W.W<?WO[L.QF:RYE1-)M(X6^5B)7#MM5GBE&$;
M6 _D(:W4V9LH^BL'[$LA$;@%_,*NW.+EP;[,.%9 HBW-#+],;4WE"0]Q,M\D
MS<Q48,8OA)F05(.HC&G :MJSRFT8,4>+<3[ 2H ?8JM36#],!=!+](D"F0;Y
M!![ :I#VFK@VJZP0P+Y,F<OU7)_SD#I7 6 #9\^ZR@I+R<ID8#6)&!+).SA!
MSCAY;.2,[]/0;H4SCHN)1.JV-;YKC]NZC,,V\.A<1/90K;>V\CD['PL(27[@
M&2<VS=ATD,=8VA48=4ALF6,+GV".M,BWJAP:"?7A4[S!'?/3EP_B%\S,\3-O
MWP8CPUX71Q_<+IA@G(3"8B.)V#[T"6^O@2.H\N(6^RJ_T:@W7I;WPRA'/-&B
MI_&X=XB/%ZVO><[X&4A Y<'@*B*;YNZ5#91WP6UAQ37SPN/C^G&K]7+>O2@-
M9.%??)N%=SWLU]O-QS[ZV.=:=?_XT?12/^>>@T_I+>$IO%"#$ ,>7(S,6MY:
M@3=#\]]\S0OK^>(/RU%HB> M.,+HZQ;?K8,)/UR*U&PA+)3> L&M8&GNR<(9
MA5\VD#.]&WT>&6 O'5ABVD.8!N(*;<??O6B^6#T#J_"K#-H37"4?R9"5]O@V
MBY>P8QG+?3>=G=483G.:;ZOA888+$^MKE/F_&#(+:8V6JX-V]S ]5S6:M>//
M_?A\LB$V$R#M*B#]((*B5JI?@M(1@9+CH/0(KS4 5@Z#.[S6>SBH2WO[I7&?
MR#",Q),<L%6-X5-F5594"P"7<)EU>S=.J7^PNCUJ+/;;&;X')V.U+CZN3Z97
M*+Y?NR>F2R'Z.1EN7KU9%/']CM=HGY"DO]B\_T\X3#A,.+R?.-PZ\AK=#@GZ
MFF!XU7EZBGC6H",?EYV'[AY\D94E\''7!]Q'XWIR[)TTR;CNA7P3^I)TNBN=
M^XB^G9;7?L3,-,DW3>;L36CSNTK-5L2B!H9[P$5FE6"'S*I+9M7O=KSN"44U
M>R'@!+\DG>Y*YS[";_?$Z_I=DF]WHQJ:L-ET5/-995CF7FM!J]+(IFX=YI!-
M73->-!LG7JM%1G4O!)S@EZ337>G<1_CU_8;7;31(P-V-:6BF9M,QS7FF@HNQ
MBD*1ZE=FVTTV=0^^R+@2]I!Q=<JX=D^\HVZ+!'P?!)S@EZ337>G<1_CM=KWC
MHX=7(B#Y?F)H Q]PPX9+>/A,A[:MLZ;S-A1>I-*F#RAM6IW*AF<*_%J=G+-0
MY-3=;FRX5J5;S* ZK/>OPXI'Q@4BR?"P=Z;'>!1><=N&>4?E3Q]?_K3=J'<Z
MCZX*VEAW5=!N'4+SM1<_]8^HF]1-A[NYEDJVMWWXOX[(Z@U_+HYZ<@1FFW.L
MVMNSI1:(>0\M+'F\O+#D4QGYX-J2&V3UALM)?AZG0K"/\'VLV3L\20Z+2E95
M;]<J_X^H+>FDCFPNN;D/"+0>[A)$.0-1Y_*: &J[5(A\VVUVSXAYSU@TG0S'
MV@S'P\]K( -!'NRN<)> R"4@>N#*" (B J)=X2X!D4M 1!Z1PZI"0$1 M"]
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M   1              "  0    !T<G9I+3(P,C4P.# W+FAT;5!+ 0(4 Q0
M   ( !.!!UOE:ON3< D  ')O   1              "  ?L4  !T<G9I+3(P
M,C4P.# W+GAS9%!+ 0(4 Q0    ( !.!!UO=#EF'E"   &Q$ @ /
M      "  9H>  !T<G9I+65X.3E?,2YH=&U02P4&      ,  P"[    6S\
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>trvi-20250807_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="trvi-20250807.xsd" xlink:type="simple"/>
    <context id="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563880</identifier>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_21415a5a-25b6-4d36-9d50-b206b674eff4">0001563880</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_2ea59ac0-636a-4812-b0df-17535db4755f">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_03521852-24fe-46e3-bcbe-cdf12f69357c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_4c2313ba-5615-4b4a-85e3-236861df663f">2025-08-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_2f4dc316-20ad-4497-b361-2aaab7e98c93">Trevi Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_6b1bb072-f980-4ea3-bc80-9eb312dc37ce">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_ef7bcaf7-2de3-4f1f-9bbd-383dd445b9a5">001-38886</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_3b7dc38e-0dd1-4be2-b801-2f7b37fe551c">45-0834299</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_796ba6fd-2d20-4e5f-9e88-142aa4bc4a25">195 Church Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_6f1819c5-3257-4b08-b3c1-5bef25aacce9">16th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_41eb83df-054e-4858-8281-4dcfb396f00c">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_e8d598c4-40a3-4969-9167-a96dbabb0d31">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_2df65019-8178-4577-9816-191e5919ed77">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_f848fa40-ab7e-4d99-92bc-5d93974706f4">(203)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_14886cf6-b687-42c4-8452-2aa095f0c058">304-2499</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_04376e39-9e3f-4469-a380-63af9c40dcbe">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_8a0eb1e7-3bdc-42fa-9005-b45955f5c179">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_e918ce6d-143f-4d96-bfdc-bbf10cdc2d14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_d393c0d1-6612-4899-9a71-e5a6520f02a1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_945c08d7-8079-4baf-94cb-993d3f58f9cb">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_f95a8cfa-fc79-4b4a-a81e-b1c0c36931b6">TRVI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_01a52a36-19dc-4f5c-b373-d348c6124db9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a6af76a8-b5f6-42cc-bfe9-771c554351ec"
      id="F_094b2159-402a-49c0-869e-b575a2e40ab9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
